United States: Ready To Release A New Pharmaceutical? What To Think About When Selecting Your Drug Name

Pharmaceutical name clearance in the United States can be complicated. This post aims to provide insight into the regulatory safety review process and the trademark registration process for candidate drug names. This information will allow drug manufacturers to make more informed decisions during the pharmaceutical name selection process so that they can arrive at a viable name, and get to market, more quickly.

Dual Tracks: FDA and PTO

A pharmaceutical manufacturer that seeks to use and register a new drug name in the United States must submit the candidate name to not one, but two, federal agencies: the U.S. Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (PTO). While both federal agencies aim to improve consumer safety by reducing the risk of consumer confusion between conflicting drug names, each agency looks at a different set of data to make its determination. The approval of a drug name by one agency has no bearing on the evaluation or approval of that name by the other agency. In addition, while PTO approval of a drug name is important, FDA approval is essential – without it, the product simply cannot be marketed in the U.S. under that name.

FDA Review

As part of the FDA's overall evaluation of a new drug, the agency assesses the manufacturer's proposed "proprietary name," or trademark, for safety risks. The primary safety risk associated with a drug name is the risk of medication error.

A medication error can occur at any point along the distribution chain – by doctors writing the prescription, pharmacists filling the prescription, or patients or health care providers administering the drug. A medication error can also occur for a variety of reasons. Perhaps the drug name suggests the frequency of administration which could conflict with a doctor's instructions. Consider a doctor that prescribes a hypothetical drug called XyzOnce for use twice a day. Will some patients be confused about how often to take the drug? Or perhaps the new drug name suggests the route of administration. If a patient receives a medication in liquid form called XyzOra, will the patient automatically assume that it is intended for oral ingestion? This could cause serious adverse consequences if the drug is, in fact, designed for topical administration. One important way the FDA seeks to reduce medication errors is to evaluate a new drug name to determine whether it looks or sounds too much like an existing drug name and whether that similarity – combined with similarities in the product characteristics – creates an undue safety risk that requires rejection of the candidate drug name.

"Look Alike" Concerns

The driving question for the "look alike" evaluation is whether two names will look similar when handwritten or entered electronically into a prescription.

The FDA considers spelling similarities such as whether two names share identical prefixes, suffixes, or infixes, and whether the names are a similar length. The FDA also considers the overall "shape" of the words. Do both names have similar looking letters in similar positions in the names – including "tall" letters ("l" "t" "f"), "round" letters ("o" "a" "c" "e" "u"), cross-stroke letters ("T" "Z" "F" "J" "I"), or down-stroke letters ("v" "r" "n" "u")? The FDA will balance these factors, along with an analysis of the phonetic similarities, to determine the overall similarity between two drug names.

"Sound Alike" Concerns

The driving question for the "sound alike" evaluation is whether two names will sound similar when spoken. What does the patient hear when the doctor tells him what medicine he has to take – and what does he repeat to the pharmacist? What does the pharmacist hear on a recorded voicemail or over a poor telephone connection? The FDA considers, among other factors, the number of syllables in the names, the placement of vowel sounds, consonant sounds, and stresses, and the placement of common sound alike letters. For example, the sound produced by "t" may be similar to the sound produced by "d" or "k". The sound produced by "b" may be similar to the sound produced by "p" "v" or "d."

Evaluation Process

To evaluate each new drug name, the FDA convenes an expert panel that reviews both objective and subjective criteria. To obtain an objective assessment of the similarity of two drug names, the FDA runs the new drug name through its Phonetic and Orthographic Computer Analysis ("POCA") database. The POCA database evaluates the candidate name against all active drug names in the U.S. market. The database assigns a percentage evaluation, ranking the new drug name on phonetic similarity, orthographic similarity, and an average of the two. Any ranking of 70% or higher will invite additional scrutiny by the agency. The FDA also conducts prescription simulation studies in which it asks volunteers to write out prescriptions, read handwritten prescriptions, and listen to voicemail recordings for the new drug name. The agency then analyzes the results to see what types of mistakes were made and how often. Safety evaluators assemble all the available data on whether the candidate name is likely to be confused with existing names, compares the product characteristics of the drugs to determine whether they have similar indications, dosages, administration methods, or storage requirements, which would increase the risk of medication errors, and make overall determinations as to whether the candidate name is likely to pose safety risks due to possible confusion with existing names.

PTO Review

When the PTO receives a new trademark application for a pharmaceutical product, a PTO attorney will evaluate the application to determine whether the new trademark is inherently registrable, whether the new trademark conflicts with a prior trademark application or registration, and whether the trademark application complies with the PTO's rules.

Inherent Registrability

For a mark to be "inherently registrable" it must be distinctive enough that consumers will perceive it as a brand name instead of a description of the underlying product. For example, consumers would be likely to perceive the hypothetical name "Cancer Drug" as merely describing what the product is (a drug to treat cancer) rather than as a brand name that identifies the manufacturer. The PTO would likely refuse this type of name on the basis that it is "merely descriptive."

The PTO also prohibits registration of names that are "deceptively misdescriptive." For example, consumers would be likely to perceive a drug called "Anti-Cancer" as being indicated for use as a treatment for cancer. That name would be "deceptively misdescriptive" if the drug were actually indicated for use as an insomnia treatment, not a cancer treatment. The PTO would thus bar registration of this name for insomnia treatments.

Conflict with Prior Marks

The PTO also evaluates new trademark applications to determine whether the trademark is likely to cause confusion with a mark in a prior registration or pending application. Due to the risk of consumer harm arising out of confusion between drug names, the PTO rules impose a stricter standard on trademark applications covering pharmaceuticals than on applications covering other types of goods, and less proof is required for the PTO to refuse a pharmaceutical application based on likelihood of confusion.

Unlike the FDA which looks at potential confusion between the candidate name and all approved brand names and generic drugs in the U.S. market, the PTO looks only at potential confusion with trademarks that are covered by an active U.S. application or registration. The PTO analyzes the risk of confusion based on a number of non-exclusive factors including, among others: (i) the similarities of the trademarks in terms of appearance, sound, meaning, and overall commercial impression, (ii) the relatedness of the goods, (iii) the similarities in the target consumers, (iv) the similarities in the trade channels, (v) whether purchases are made on impulse or after careful consideration, and (vi) the number and nature of similar marks used on similar goods.

The first two factors are typically the most important and they operate on a sliding scale: the more similar the marks are, the less similar the goods must be for the PTO to find a "likelihood of confusion." The PTO considers the overall visual, phonetic, and conceptual impression created by two trademarks; it does not do a letter-by-letter analysis like the FDA. Similarly, in evaluating the similarity of the goods, the PTO is bound by the description of goods identified in the respective trademark filings. Unless the description of goods in a trademark filing specifies a mode of administration (i.e., "by injection") or a specific trade channel (i.e., "administered by health care professionals in a clinical setting"), the PTO will not consider such distinctions in evaluating the relatedness of the goods.

Compliance with PTO Rules

To proceed to registration, a trademark application must also comply with a number of technical rules at the PTO. Two rules that can trip up pharmaceutical trademark applicants are the rules to identify the goods with "particularity" and the rules to show use of the mark in commerce.

The PTO requires that trademark applicants specify the nature and purpose of the drug. In other jurisdictions, the description "pharmaceutical preparations" may be acceptable, but the PTO requires more specificity, such as "pharmaceutical preparations, namely, anti-depressants." It is possible to register similar marks for pharmaceuticals covering unrelated indications.

The PTO is relatively unique in that it requires proof that a trademark has been "used in commerce" prior to issuance of a registration. In the pharmaceutical context, shipments of branded drugs to clinical investigators during the regulatory approval process is considered "use in commerce." Trademark applicants that file a U.S. application through the Madrid Protocol or based on a registration in the applicant's home country are not required to submit evidence of use prior to issuance of a registration.

Practical Tips

To streamline the process to regulatory approval and trademark registration for a candidate drug name, pharmaceutical manufacturers may consider adopting the following practices:

  • Start the name clearance process as early as possible to leave sufficient time to conduct preliminary trademark clearance searches, full trademark clearance searches, and to file trademark applications prior to submitting the name for regulatory approval.
  • Have many backup names comprised of a variety of prefixes, suffixes, and infixes, to reduce the risk that a particular prior mark would block multiple candidate names. It is not uncommon for pharmaceutical manufacturers to start with a list of more than 20 candidate names.
  • Consider repurposing a name that was cleared for a prior drug, but not utilized.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions